Emanuelle Wakselman

Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis.

T. Christophe, C. Menet, B. Allart, 2021, Journal of medicinal chemistry.

Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.

J. Steyaert, N. Triballeau, K. Conrath, 2017, Journal of medicinal chemistry.

Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic.

L. Nelles, S. Dupont, N. Triballeau, 2014, Journal of medicinal chemistry.

Discovery of 9-cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial.

L. Nelles, G. Milligan, S. Dupont, 2020, Journal of medicinal chemistry.

Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment

S. Dupont, N. Desroy, R. Blanqué, 2015 .

Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fib

N. Triballeau, M. Lamers, B. Hrvačić, 2017, Journal of medicinal chemistry.

Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic Diseases.

N. Triballeau, Denis Bucher, T. Christophe, 2021, Journal of medicinal chemistry.